B.S. Glisson

516 total citations
10 papers, 357 citations indexed

About

B.S. Glisson is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, B.S. Glisson has authored 10 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in B.S. Glisson's work include Lung Cancer Research Studies (6 papers), Neuroendocrine Tumor Research Advances (3 papers) and Peptidase Inhibition and Analysis (3 papers). B.S. Glisson is often cited by papers focused on Lung Cancer Research Studies (6 papers), Neuroendocrine Tumor Research Advances (3 papers) and Peptidase Inhibition and Analysis (3 papers). B.S. Glisson collaborates with scholars based in United States, Germany and France. B.S. Glisson's co-authors include Arlene A. Forastiere, Jay S. Cooper, John A. Ridge, Randal S. Weber, Thomas F. Pajak, Celia Chao, John F. Ensley, Moshe Maor, Andy Trotti and Adam S. Garden and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Lung Cancer.

In The Last Decade

B.S. Glisson

10 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B.S. Glisson United States 7 258 173 169 166 47 10 357
T. Nwizu United States 11 276 1.1× 167 1.0× 109 0.6× 140 0.8× 41 0.9× 23 340
F. Rosen United States 6 314 1.2× 219 1.3× 152 0.9× 118 0.7× 58 1.2× 10 399
Christian Sire France 11 224 0.9× 108 0.6× 191 1.1× 124 0.7× 34 0.7× 21 329
Ch. Popella Germany 3 454 1.8× 327 1.9× 181 1.1× 210 1.3× 33 0.7× 4 504
Tod W. Speer United States 5 348 1.3× 302 1.7× 130 0.8× 124 0.7× 17 0.4× 10 432
Luciana Lastrucci Italy 9 250 1.0× 131 0.8× 111 0.7× 179 1.1× 38 0.8× 12 344
Charissa Goh Singapore 5 273 1.1× 196 1.1× 124 0.7× 102 0.6× 14 0.3× 14 325
Harsh Dhar India 9 119 0.5× 98 0.6× 69 0.4× 65 0.4× 48 1.0× 24 256
Joaquín Belón Spain 4 280 1.1× 215 1.2× 164 1.0× 104 0.6× 36 0.8× 4 348
M. A. Carroll United States 7 389 1.5× 334 1.9× 184 1.1× 170 1.0× 30 0.6× 11 482

Countries citing papers authored by B.S. Glisson

Since Specialization
Citations

This map shows the geographic impact of B.S. Glisson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B.S. Glisson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B.S. Glisson more than expected).

Fields of papers citing papers by B.S. Glisson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B.S. Glisson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B.S. Glisson. The network helps show where B.S. Glisson may publish in the future.

Co-authorship network of co-authors of B.S. Glisson

This figure shows the co-authorship network connecting the top 25 collaborators of B.S. Glisson. A scholar is included among the top collaborators of B.S. Glisson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B.S. Glisson. B.S. Glisson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
2.
Pietanza, M. Catherine, David R. Spigel, Tyler M. Bauer, et al.. (2015). 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). European Journal of Cancer. 51. S712–S712. 12 indexed citations
3.
Forastiere, Arlene A., Moshe Maor, Randal S. Weber, et al.. (2006). Long-term results of Intergroup RTOG 91–11: A phase III trial to preserve the larynx—Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Journal of Clinical Oncology. 24(18_suppl). 5517–5517. 125 indexed citations
4.
Blumenschein, G. R., M.S. Kies, B.S. Glisson, et al.. (2004). Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer(SCCHN). Journal of Clinical Oncology. 22(14_suppl). 5578–5578. 9 indexed citations
5.
Garden, Adam S., Jonathan Harris, Everett E. Vokes, et al.. (2004). Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck. Journal of Clinical Oncology. 22(14). 2856–2864. 147 indexed citations
6.
Zinner, Ralph, B.S. Glisson, Katherine M.W. Pisters, et al.. (2001). Cisplatin and gemcitabine combined with herceptin in patients (pt) with her2 overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC): a phase II trial. European Journal of Cancer. 37. S154–S154. 17 indexed citations
7.
8.
Roth, Jack A., S.G. Swisher, David Lawrence, et al.. (1997). Gene replacement for lung cancer. Lung Cancer. 18. 76–76. 1 indexed citations
9.
Perez‐Soler, R., et al.. (1993). Phase II study of topotecan in patients with non-small cell lung cancer. European Journal of Cancer. 29. S162–S162. 2 indexed citations
10.
Lee, JS, et al.. (1990). Primary chemotherapy of brain metastasis in small-cell lung cancer. Lung Cancer. 6(1-2). 59–59. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. Nwizu Breakdown of academic impact, for papers by F. Rosen Breakdown of academic impact, for papers by Christian Sire Breakdown of academic impact, for papers by Ch. Popella Breakdown of academic impact, for papers by Tod W. Speer Breakdown of academic impact, for papers by Luciana Lastrucci Breakdown of academic impact, for papers by Charissa Goh Breakdown of academic impact, for papers by Harsh Dhar Breakdown of academic impact, for papers by Joaquín Belón Breakdown of academic impact, for papers by M. A. Carroll
Rankless by CCL
2026